In patients with malignant melanoma, breast, esophageal, and prostate cancer, survivin expression is positively modulated and very often correlated with poor response to anticancer therapy, disease recurrence, and decreased overall survival [88,89,90,91]. Here, BIRC5 is linked to melanoma.